Fifteen brokerages covering C3.ai have assigned the stock a consensus recommendation of “Reduce,” including five sell ratings, seven holds, two buys and one strong buy, according to Marketbeat. This mix of ratings underscores growing caution among analysts about the company’s near-term growth prospects in enterprise AI deployments.

In the past quarter, UBS Group raised its target on C3.ai from $16.00 to $17.00 while maintaining a neutral stance, whereas Wedbush upheld an outperform rating with a $20.00 target. Canaccord Genuity and Needham & Company both reaffirmed hold ratings with $16.00 objectives. The average one-year price objective across all reports stands at $21.92.

CEO Stephen Bradley Ehikian sold 234,918 shares at an aggregate value of $3.19 million on December 31st, trimming his stake by 20.27%. Chairman Thomas M. Siebel disposed of 554,802 shares at a total of $10.44 million on October 14th, reducing his holding by 22.10%. Insiders have sold 1.95 million shares worth $30.85 million over the past 90 days, leaving them with 26.50% ownership.

Several hedge funds took new or larger positions this year: Silicon Valley Capital Partners initiated a $25,000 stake in Q2; Larson Financial Group boosted its position by 683.6% to 1,481 shares; Parallel Advisors added 801 shares for a 76.4% increase; Financial Consulate entered with $36,000; and Clearstead Advisors lifted its holding by 58.0% to 2,350 shares. Institutions now own 38.96% of the company.